Home › Mielofibrosi › Kansas
Studi clinici su Mielofibrosi nello stato di Kansas
6 studi su Mielofibrosi cercano partecipanti presso sedi nello stato di Kansas.
Testo ufficiale dello studio (inglese)
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- e altri 1
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT06661915A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- University of Kansas Medical Center, Kansas City
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT06343805Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined
- The University of Kansas Cancer Center, Fairway
In reclutamentoFase 1 inizialeVolontari sani benvenuti
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 mag 2026 · NCT06414681A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- The University of Kansas Cancer Center, Westwood
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 apr 2026 · NCT06034002A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Kansas Medical Center, Westwood
In reclutamentoFase 2
Età da 18 a 66 · Tutti i sessi · Aggiornato il 17 mar 2026 · NCT06859424Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- University of Kansas Cancer Center - Westwood, Westwood
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2025 · NCT06479135Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.